PL4025187T3 - Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu - Google Patents
Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiuInfo
- Publication number
- PL4025187T3 PL4025187T3 PL21724651.1T PL21724651T PL4025187T3 PL 4025187 T3 PL4025187 T3 PL 4025187T3 PL 21724651 T PL21724651 T PL 21724651T PL 4025187 T3 PL4025187 T3 PL 4025187T3
- Authority
- PL
- Poland
- Prior art keywords
- extended release
- dosing regimens
- injectable formulations
- regimens associated
- release paliperidone
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 239000007972 injectable composition Substances 0.000 title 1
- 229960001057 paliperidone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119382P | 2020-11-30 | 2020-11-30 | |
| PCT/EP2021/062144 WO2022111858A1 (en) | 2020-11-30 | 2021-05-07 | Dosing regimens associated with extended release paliperidone injectable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4025187T3 true PL4025187T3 (pl) | 2024-04-29 |
Family
ID=75888042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21724651.1T PL4025187T3 (pl) | 2020-11-30 | 2021-05-07 | Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11324751B1 (pl) |
| EP (2) | EP4025187B1 (pl) |
| JP (1) | JP2023552149A (pl) |
| KR (1) | KR20230116837A (pl) |
| CN (1) | CN116507320A (pl) |
| AU (2) | AU2021387679B2 (pl) |
| CA (1) | CA3203448A1 (pl) |
| DK (1) | DK4025187T3 (pl) |
| ES (1) | ES2974822T3 (pl) |
| FI (1) | FI4025187T3 (pl) |
| HR (1) | HRP20240086T1 (pl) |
| HU (1) | HUE065387T2 (pl) |
| IL (1) | IL303251A (pl) |
| LT (1) | LT4025187T (pl) |
| MX (1) | MX2023006370A (pl) |
| PL (1) | PL4025187T3 (pl) |
| PT (1) | PT4025187T (pl) |
| RS (1) | RS65133B1 (pl) |
| SI (1) | SI4025187T1 (pl) |
| TW (1) | TWI838623B (pl) |
| WO (1) | WO2022111858A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023006368A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| WO2022112367A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Methods for ensuring resuspension of paliperidone palmitate formulations |
| KR20240052810A (ko) * | 2021-08-30 | 2024-04-23 | 얀센 파마슈티카 엔브이 | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| CN101163702B (zh) | 2005-04-25 | 2011-09-07 | 詹森药业有限公司 | 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法 |
| RS61765B1 (sr) | 2007-12-19 | 2021-05-31 | Janssen Pharmaceutica Nv | Režim doziranja povezan sa dugodelujućim injektabilnim estrima paliperidona |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| JP2013509435A (ja) | 2009-10-30 | 2013-03-14 | ヤンセン ファーマシューティカ エヌ．ベー． | 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン |
| PT2529757E (pt) | 2011-05-31 | 2014-02-27 | Rovi Lab Farmaceut Sa | Formulação para implante de paliperidona |
| WO2016157061A1 (en) | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| HUE049485T2 (hu) * | 2015-04-07 | 2020-09-28 | Janssen Pharmaceuticals Inc | Adagolási rend hosszan ható, injektálható paliperidon-észterek beadásának elmaradása esetén |
| WO2019118722A1 (en) * | 2017-12-14 | 2019-06-20 | SpecGx LLC | One step milling process for preparing micronized paliperidone esters |
-
2021
- 2021-05-07 PL PL21724651.1T patent/PL4025187T3/pl unknown
- 2021-05-07 CA CA3203448A patent/CA3203448A1/en active Pending
- 2021-05-07 LT LTEPPCT/EP2021/062144T patent/LT4025187T/lt unknown
- 2021-05-07 AU AU2021387679A patent/AU2021387679B2/en active Active
- 2021-05-07 WO PCT/EP2021/062144 patent/WO2022111858A1/en active Application Filing
- 2021-05-07 MX MX2023006370A patent/MX2023006370A/es unknown
- 2021-05-07 KR KR1020237021416A patent/KR20230116837A/ko not_active Application Discontinuation
- 2021-05-07 PT PT217246511T patent/PT4025187T/pt unknown
- 2021-05-07 HU HUE21724651A patent/HUE065387T2/hu unknown
- 2021-05-07 JP JP2023532443A patent/JP2023552149A/ja active Pending
- 2021-05-07 TW TW110116513A patent/TWI838623B/zh active
- 2021-05-07 RS RS20240087A patent/RS65133B1/sr unknown
- 2021-05-07 US US17/314,281 patent/US11324751B1/en active Active
- 2021-05-07 FI FIEP21724651.1T patent/FI4025187T3/fi active
- 2021-05-07 SI SI202130112T patent/SI4025187T1/sl unknown
- 2021-05-07 ES ES21724651T patent/ES2974822T3/es active Active
- 2021-05-07 CN CN202180080436.4A patent/CN116507320A/zh active Pending
- 2021-05-07 EP EP21724651.1A patent/EP4025187B1/en active Active
- 2021-05-07 HR HRP20240086TT patent/HRP20240086T1/hr unknown
- 2021-05-07 EP EP23219073.6A patent/EP4385564A3/en active Pending
- 2021-05-07 DK DK21724651.1T patent/DK4025187T3/da active
- 2021-05-07 IL IL303251A patent/IL303251A/en unknown
-
2022
- 2022-05-06 US US17/738,422 patent/US20230105276A1/en active Pending
-
2024
- 2024-04-10 AU AU2024202306A patent/AU2024202306A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023552149A (ja) | 2023-12-14 |
| US20230105276A1 (en) | 2023-04-06 |
| IL303251A (en) | 2023-07-01 |
| EP4025187A1 (en) | 2022-07-13 |
| HRP20240086T1 (hr) | 2024-03-29 |
| AU2024202306A1 (en) | 2024-05-02 |
| TW202222318A (zh) | 2022-06-16 |
| DK4025187T3 (da) | 2024-03-04 |
| KR20230116837A (ko) | 2023-08-04 |
| US11324751B1 (en) | 2022-05-10 |
| EP4385564A2 (en) | 2024-06-19 |
| ES2974822T3 (es) | 2024-07-01 |
| HUE065387T2 (hu) | 2024-05-28 |
| PT4025187T (pt) | 2024-02-28 |
| AU2021387679B2 (en) | 2024-01-18 |
| TWI838623B (zh) | 2024-04-11 |
| FI4025187T3 (fi) | 2024-02-13 |
| EP4385564A3 (en) | 2024-10-09 |
| SI4025187T1 (sl) | 2024-03-29 |
| RS65133B1 (sr) | 2024-02-29 |
| AU2021387679A1 (en) | 2023-07-20 |
| LT4025187T (lt) | 2024-02-12 |
| MX2023006370A (es) | 2023-08-07 |
| EP4025187B1 (en) | 2024-01-03 |
| WO2022111858A1 (en) | 2022-06-02 |
| CN116507320A (zh) | 2023-07-28 |
| US20220168306A1 (en) | 2022-06-02 |
| CA3203448A1 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT4025187T (pt) | Regimes de administração associados a formulações injetáveis de paliperidona de libertação prolongada | |
| SI4025188T1 (sl) | Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem | |
| AU2021387679A9 (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| IL206448A0 (en) | Dosing regimen associated with long acting injectable paliperidone esters | |
| HK1249047A1 (zh) | 用於長效可注射的帕利酮酯的遺漏劑量的投藥療程 | |
| IL269844A (en) | Dosage regimens and related preparations and methods | |
| PL4025189T3 (pl) | Schematy dawkowania związane z preparatami paliperydonu o przedłużonym uwalnianiu do wstrzykiwania | |
| IL277744A (en) | Pyrazolotriazolopyrimidine derivatives as A2A receptor inhibitors | |
| HK1199878A1 (en) | Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists | |
| IL280515A (en) | Dosing regimens for algolix | |
| IL311134A (en) | Dosing regimens associated with delayed-release paliperidone injection formulations | |
| IL308095A (en) | Dosing regimens | |
| GB202013571D0 (en) | Injectable formulation | |
| HUP2100259A1 (hu) | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |